A patent review of BRAF inhibitors: 2013-2018. (3rd August 2019)

• Record Type: Journal Article
• Authors: Wang, Peng-Fei; Qiu, Han-Yue; Zhu, Hai-Liang
• Is Part Of: Expert opinion on therapeutic patents. Volume 29:Number 8(2019)
• Page Start: 595
• Page End: 603
• Publication Date: 2019-08-03
• Subjects: Anti-tumor -- BRAFi -- combination -- pan-RAF -- paradox-breaker -- paradoxical effect -- resistance; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2019.1640680
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : As a key element in arguably the most important pathway MAPK signaling, the BRAF kinase gives rise to severe diseases including cancers when pathologically activated. Extensive research on BRAFi (BRAF inhibitor) has been carried out to profile the characters for optimized agents and to elaborate the therapeutic strategies for the related cancer treatment. Areas covered : This review gives an overview of recently approved BRAF agents on function mode, therapeutic efficacy, and deficiency, based on which current challenges and corresponding strategies were presented. New entities as BRAFi for medical purpose in patent literature during the period 2013–2018 were also briefly introduced. Expert opinion : With the disclosure of paradox-breaker BRAFi PLX7904 crystal in complex with BRAF, the rational design for next-generation BRAFi is becoming ever more feasible. Accompanying therapeutic strategies in BRAFi elaboration may also provide flexible choice in the future 'personal medicine'. Further digging in the greatly enriched BRAFi pool will greatly benefit the drug design processes such as FBDD- and SBDD-driven development.